Loading stock…

Moderna, Inc. (MRNA) Stock Verdict & Ratings | Investment Bastion

02Growth

Is it actually growing, and how fast?

MRNAModerna

Revenue FY25$3.2B

GROWTH RATING↗

AVERAGE59 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-53%1

Revenue, next 1Y+9%6

Revenue, next 3Y, CAGR+16%8

Revenue, next 5Y, CAGR+21%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

Revenue is set to grow 16%/yr over the next 3 years, ahead of most of the market.8/10

After shrinking over the last 3 years, revenue is set to grow 16%/yr from here.

The runway holds up: revenue is set to grow 21%/yr over five years.9/10

WATCH

A mid-pack grower, ahead of 59% of companies worldwide.

WEAKNESSES

Revenue fell 53%/yr over the last 3 years, behind 90% of companies worldwide.1/10

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A middle-of-the-pack grower that's turning around. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG89 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+40%10

3-month return+166%10

YTD return+566%10

MID & LONG-TERM▾SCORE

% of 52-week high93%9

1-year return+604%10

3-year return+89%7

5-year return-36%2

MOMENTUM ASSESSMENT

STRENGTHS

It's up 604% over the past year, now 7% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+40%), over three months (+166%) and so far this year (+566%).

WATCH

Average long-term results. Multi-year returns are middling (+89% over three years and -36% over five), roughly average for the market.

WEAKNESSES

None flagged.

BOTTOM LINE

Fresh Momentum

Short-term returns are strong but the long track record is thin. Momentum is building — confirmation from longer horizons would strengthen the case.

04Value

Are you paying a fair price for it?

Stop guessing on Moderna. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

MRNAModerna

Revenue FY25$3.2B

GROWTH RATING↗

AVERAGE59 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-53%1

Revenue, next 1Y+9%6

Revenue, next 3Y, CAGR+16%8

Revenue, next 5Y, CAGR+21%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

Revenue is set to grow 16%/yr over the next 3 years, ahead of most of the market.8/10

After shrinking over the last 3 years, revenue is set to grow 16%/yr from here.

The runway holds up: revenue is set to grow 21%/yr over five years.9/10

WATCH

A mid-pack grower, ahead of 59% of companies worldwide.

WEAKNESSES

Revenue fell 53%/yr over the last 3 years, behind 90% of companies worldwide.1/10

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A middle-of-the-pack grower that's turning around. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG89 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+40%10

3-month return+166%10

YTD return+566%10

MID & LONG-TERM▾SCORE

% of 52-week high93%9

1-year return+604%10

3-year return+89%7

5-year return-36%2

MOMENTUM ASSESSMENT

STRENGTHS

It's up 604% over the past year, now 7% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+40%), over three months (+166%) and so far this year (+566%).

WATCH

Average long-term results. Multi-year returns are middling (+89% over three years and -36% over five), roughly average for the market.

WEAKNESSES

None flagged.

BOTTOM LINE

Fresh Momentum

Short-term returns are strong but the long track record is thin. Momentum is building — confirmation from longer horizons would strengthen the case.

04Value

Are you paying a fair price for it?

Stop guessing on Moderna. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Moderna, Inc.

01Key Ratings

02Growth

03Price Momentum

04Value

Stop guessing on Moderna. Get the full investment case.

Premium

02Growth

03Price Momentum

04Value

Stop guessing on Moderna. Get the full investment case.

Premium